Tumour invasion involves many interactions between tumour cells and extracellular matrix (ECM). It is mediated through specific events including receptor-mediated recognition, attachment and ECM degradation, leading to the migration of cells towards a chemotactic agent ([@bib40]).

Elastin has a key role in matrix biology. It is the major component of elastic fibres, particularly abundant in tissues such as arteries and lung, and also present in skin, breast, cartilage and some ligaments. It is a long-lived macromolecule with no detectable turnover ([@bib33]). Its proteolysis by elastase-type proteinases (metallo, serine and cysteine families) is linked to the genesis of several diseases affecting elastin-rich organs ([@bib48]; [@bib46]). This degradation is known to unmask cryptic sites within the ECM and to release matrikines, termed elastin-derived peptides (EDPs or elastokines). These EDPs display a wide range of biological activities, influencing cell migration ([@bib36]; [@bib20]), differentiation ([@bib16]), proliferation, chemotaxis ([@bib24]; [@bib27]), survival, tumour progression ([@bib42]; [@bib21]; [@bib29]), angiogenesis ([@bib32]), aneurysm formation and atherogenesis ([@bib31]; [@bib28]; [@bib18]). With regard to tumour invasion, soluble peptides obtained from alkaline (*κ*-elastin) or elastase hydrolysis of insoluble elastin, as well as tropoelastin, were shown to increase MMP-1, MMP-2 and MMP-3 production by human skin fibroblasts ([@bib4]; [@bib22]). Similarly, EDPs stimulated MMP-2, MT1-MMP and TIMP-2 secretion in human HT-1080 fibrosarcoma cell line and, as a consequence, could promote the invasive and metastatic properties of tumour cells ([@bib5]; [@bib21]). Cell responses to EDPs were attributed to the binding of a VGVAPG hexapeptide sequence, repeated several times in tropoelastin, to elastin receptors with lectin-like properties, named the elastin receptor complex (S-Gal/neuraminidase/ cathepsin A protective protein) or galectin-3. Nevertheless, two other elastin receptors have recently been described ([@bib27]; [@bib2]). The first one, unaffected by lactose and heparin sulphate, was identified as integrin *α*V*β*3. It is involved in the divalent cation-dependent adhesion of human dermal fibroblast to the C-terminal GRKRK motif of tropoelastin. The second one, a lactose-insensitive receptor unknown to date, binds elastin-derived nonapeptides (AGVPGLGVG and AGVPGFGAG) and modulates macrophage migration ([@bib27]) and lung cancer cells MMP-2 and urokinase plasminogen activator (uPA) secretion ([@bib43]).

As shown in our previous studies, EDPs increase the secretion of MMP-2 and uPA by HT-1080 cells and induce or potentiate MMP activation cascades in the presence of plasminogen ([@bib21]). Accumulating evidences indicate that Hsp90 has important roles in both physiological and pathological processes, especially in tumour progression ([@bib44]). Heat-shock protein 90 is a highly conserved and abundant protein, constituting about 1% of the total intracellular protein ([@bib17]). In the cytosol, two isoforms of Hsp90 are referred to as Hsp90*α* and Hsp90*β* ([@bib7]). Intriguingly, the Hsp90*α* isoform also exists extracellularly ([@bib44]). Heat-shock protein 90 is secreted by neuron cells, dermal fibroblasts, keratinocytes, macrophages and epithelial cells. It participates in neuronal cell migration, wound healing and viral and bacteria infection. Heat-shock protein 90*α* can be detected in the blood of cancer patients, and the level of Hsp90*α* is positively associated with tumour malignancy ([@bib47]). [@bib47] reported that extracellular Hsp90*α* can interact with MMP-2 and that immobilised geldanamycin, an impermeable inhibitor of Hsp90*α*, inhibits MMP-2 proteolytic activity. More recently, [@bib39] and [@bib38] demonstrated that extracellular Hsp90 modulates the MMP-2-dependent tumour processes by enhancing MMP-2 activation, stabilising and preventing MMP-2 inactivation processing.

In the present study, our aim was to determine if EDPs were also able to increase the extracellular presence of Hsp90 and to induce MMP-2 and uPA accumulation in the cell culture medium through the formation of an extracellular Hsp90/MMP-2/uPA complex. We demonstrate that the presence of kappa-elastin (Kel) and VGVAPG stimulates Hsp90 secretion. Heat-shock protein 90 upregulation followed by EDP treatment generated MMP-2 and uPA accumulation, thereby strongly potentiating cancer cell migration and matrix invasion capacities.

Materials and methods
=====================

Reagents
--------

Synthetic elastin peptides (VGVAPG, AGVPGLGVG and GRKRK) were purchased from Proteogenix (Schiltigheim, France). Matrigel was obtained from Becton-Dickinson (Le Pont de Claix, France). Plasminogen, mouse anti-MMP-2 and anti-uPA antibodies were obtained from Calbiochem (distributed by VWR, Strasbourg, France). Geldanamycin was obtained from Invivogen (Toulouse, France). Radicicol was purchased from Tebu-bio (Le Perray-en-Yvelines, France). Rabbit monoclonal anti-Hsp90 was from Ozyme (Saint Quentin Yvelines, France). Mouse anti-Hsp90 was purchased from Abcam (Paris, France). Goat anti-actin was from Santa Cruz (Heidelberg, Germany). Recombinant Hsp90*α* protein was from Enzo Life Sciences (Villeurbanne, France).

Materials
---------

Insoluble elastin was prepared from bovine ligamentum nuchae by hot alkali treatment and its purity was assessed by amino-acid analysis and lack of hexoses and hexosamines in the preparation ([@bib23]). Soluble Kel peptides were obtained from purified insoluble elastin by organoalkaline hydrolysis ([@bib34]). Peptides with an average molecular weight of 75 kDa were isolated by gel permeation on Sephadex G100 (Sigma-Aldrich, Saint Quentin Fallavier, France).

Cell culture
------------

Human fibrosarcoma cells (HT-1080) and breast carcinoma cells (MDA-MB-231) were obtained from the American Type Culture Collection (Rockville, MD, USA). They were cultured in Dulbecco\'s modified Eagle\'s medium (DMEM; Gibco-BRL, Fisher Scientific, Illkirch, France) supplemented with 10% fetal calf serum.

Preparation of conditioned media
--------------------------------

Cells were grown to subconfluency in 24-well culture plates (Nunc, represented in France by Polylabo, Strasbourg) in 10% serum-containing medium. After 16 h in serum-free medium, soluble substrates,that is, Kel (from 1 to 100 *μ*g ml^−1^) or elastin synthetic peptides (200 *μ*g ml^−1^), were added to serum-free culture medium, and HT-1080 cells were incubated for 6--48 h, in the presence or absence of 1.5 *μ*[M]{.smallcaps} geldanamycin, 10 *μ*[M]{.smallcaps} radicicol, 0.1--10 *μ*g ml^−1^ mouse anti-Hsp90 antibody and 1--50 *μ*g ml^−1^ recombinant Hsp90*α*. Conditioned media were harvested and centrifuged at 10 000 **g** for 10 min at room temperature to remove cellular debris. They were used for the determination of Hsp90, MMP-2 and uPA secretion.

Gelatin zymography
------------------

Conditioned media from HT-1080 cell cultures were analysed for gelatin degradation by electrophoresis under non-reducing conditions on an SDS--polyacrylamide gel containing 1 mg ml^−1^ gelatin. The volume of conditioned medium loaded per lane was standardised on the basis of the cell count at harvest. Gels were incubated overnight at room temperature in 50 m[M]{.smallcaps} Tris-HCl, 150 m[M]{.smallcaps} NaCl and 10 m[M]{.smallcaps} CaCl~2~ (pH 7.4). White lysis zones, indicative of degrading activity, were revealed by staining with Coomassie brilliant blue.

Gelatin plasminogen zymography
------------------------------

For the determination of plasminogen activators, conditioned media were analysed on SDS--polyacrylamide gels containing 1 mg ml^−1^ gelatin and 3 *μ*g ml^−1^ plasminogen. Following electrophoresis, gels were incubated overnight at room temperature in 100 m[M]{.smallcaps} glycine buffer and EDTA 5 m[M]{.smallcaps} (pH 8.3). Gelatinolytic activity resulting from plasminogen activation was indicated here by white lysis zones, which were revealed by staining with Coomassie brilliant blue. As a positive control, recombinant urokinase was used; as a negative control, 2 m[M]{.smallcaps} phenylmethylsulphonylfluoride was added to the incubation buffer.

Western blot analysis
---------------------

Conditioned media were concentrated in Vivaspin from Sartorius stedim (Aubagne, France) and samples were electrophoresed in a 0.1% SDS and 10% polyacrylamide gel, under reducing conditions. Proteins were then transferred onto Immobilon-P membrane (Millipore, Saint-Quentin en Yvelines, France). The membrane was blocked with 5% non-fat dry milk, 0.1% Tween-20 in a 50 m[M]{.smallcaps} Tris-HCl buffer and 150 m[M]{.smallcaps} NaCl (pH 7.5) (TBS) for 2 h at room temperature, incubated overnight at +4 °C with anti-Hsp90, anti-MMP-2 or anti-uPA antibody and then for 1 h at room temperature with a second peroxidase-conjugated anti-IgG antibody. Immune complexes were visualised with the ECL Chemoluminescence Detection Kit (GE Healthcare, Orsay, France).

Hsp90, pro-MMP-2 and uPA detection by immunocytofluorescence
------------------------------------------------------------

HT-1080 cells were plated on glass slides and incubated in 10% serum-containing medium. After 16 h in serum-containing medium, 50 *μ*g ml^−1^ Kel were added to serum-free culture medium, and HT-1080 cells were incubated for 30 min. They were fixed for 5 min with 4% paraformaldehyde. The slides were washed with PBS-T and saturated in PBS-T with 5% BSA. Cells were then incubated for 1 h at room temperature with an anti-HSP90, anti-MMP-2 and anti-uPA antibody diluted 1/400 in PBS-T with 1% BSA. Slides were washed in PBS-T and cells were incubated for 30 min with the Alexa-488- or Alexa-568-conjugated secondary antibodies diluted 1/1000 in TBS-T with 1% BSA. Cells were then washed with PBS-T. Control preparations were incubated with omission of the first antibody. Immunofluorescence-labelled cell preparations were studied using a Zeiss LSM 710 confocal laser scanning microscope with the × 60 oil-immersion objective (Carl Zeiss Microimaging, Heidelberg, Germany).

Primer design for RT--qPCR
--------------------------

Real-time quantitative polymerase chain reaction (RT-qPCR) primers were designed according to sequences of Hsp90α transcript-1 (*Hsp90AA1-001*) and Hsp90α transcript-2 (*Hsp90AA1-002*) (NM_001017963), MMP-2 (NM_004530), uPA (NM_001145031) and EEFa1 (NM_001402). The forward primer for Hsp90α transcript-1 was 5′-GCCTTCAGACAGAGCCAAGGT-3′ and the reverse primer was 5′-TCTTGGGTCTGGGTTTCCTCA-3′ with a 101 bp product. The forward primer for Hsp90α transcript-2 was 5′-CGTCAGTTGCTTCAGCGTCC-3′ and the reverse primer was 5′-TCAACTGGGCAATTTCTGCCT-3′ with a 151 bp product. The forward primer for MMP-2 was 5′-TCTTCCCCTTCACTTTCCTG-3′ and the reverse primer was 5′-ACTTGCGGTCGTCATCGTA-3′ with a 111 bp product. The forward primer for uPA was 5′-CCCAGTTTGGCACAAGCTGT-3′ and the reverse primer was 5′-CCCTGGCAGGAATCTGTTTTC-3′ with a 202 bp product. The forward primer for EEF1a1 was 5′-CTGGAGCCAAGTGCTAACATGCC-3′ and the reverse primer was 5′-CCGGGTTTGAGAACACCAGTC-3′ with a 221 bp product. All primers were synthesised by Eurogentec (Maine Et Loire, France).

RT--qPCR
--------

Total RNA isolation was performed using the Qiagen RNeasy Kit (Qiagen, Courtaboeuf, France) according to the manufacturer\'s instructions. Complementary DNA was prepared from 200 ng of total RNA by reverse transcription (RT) using a Maxima First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Villebon-sur-Yvette, France) according to the manufacturer\'s protocol. Real-time PCR was performed using a Maxima SYBR GREEN/ROX qPCR Master Mix (Thermo Fisher Scientific) on the Stratagene Mx3005P qPCR detection system (Agilent Technologies, Les Ulis, France). Polymerase chain reaction conditions were 15 min at +95 °C, followed by 40 cycles each consisting of 15 s at +95 °C (denaturation) and 30 s at +60 °C (annealing/extension). Polymerase chain reaction efficiency of the primer sets (Hsp90α transcript-1, Hsp90α transcript-2, MMP-2, uPA and EEF1a1) was controlled via the slope of a standard curve. Results were standardised to the EEF1a1 gene expression level. Relative gene expression was determined with the formula fold induction=2−ΔΔCt, where ΔΔCt=(Ct GI (unknown sample)−Ct GI (reference sample))−(Ct GR (unknown sample)−Ct GR (reference sample)). GI represents the Gene of Interest and GR the Reference Gene. The entire experiment from RNA extraction to real-time PCR steps was repeated four times with different sets of samples.

siRNA transfection
------------------

Small interfering RNA specific to human Hsp90α (FlexiTube GeneSolution GS3320 for HSP90AA1) and negative control siRNA (non-targeting pool), which do not target any genes, were purchased from Qiagen. The siRNA target different regions of the Hsp90α mRNA: 1st siRNA target sequence (5′-AACCCTGACCATTCCATTATT-3′), 2nd siRNA target sequence (5′-TGCACTGTAAGACGTATGTAA-3′), 3rd siRNA target sequence (5′-CAGAATGAAGGAGAACCAGAA-3′) and 4th siRNA target sequence (5′-ATGGCATGACAACTACTTTAA-3′). Exponentially growing HT-1080 cells were transfected with two siRNA pools (SiRNA1: 1st and 2nd siRNA target sequences/siRNA2: 3rd and 4th siRNA target sequences) (20 n[M]{.smallcaps}) (Qiagen) using Lipofectamine 2000 (Life Technologies, Fisher Scientific). Decrease of Hsp90α mRNA expression was assessed by RT--qPCR at 48 h after transfection. Decrease of Hsp90 protein expression was monitored by western blotting and immunocytofluorescence 72 h after siRNA transfection. Cells were subjected to EDP treatment for pro-MMP-2 and uPA secretion 48 h after transfection.

Artificial wound assay
----------------------

HT-1080 cells were seeded on uncoated 12-well plates in 10% serum-containing medium. A homogeneous wound was created in each well by scraping cells with a tip followed by two washes with DMEM to eliminate dead cells and cellular debris. Soluble substrates, that is, Kel (50 *μ*g ml^−1^), were added to serum-free culture medium and HT-1080 cells were incubated for 24 h, in the presence or absence of 1.5 *μ*[M]{.smallcaps} geldanamycin or 10 *μ*[M]{.smallcaps} radicicol. Wound closure was evaluated by videomicroscopy (Axiovert 200 [M]{.smallcaps}; Zeiss).

*In vitro* invasion assay
-------------------------

Invasion was assessed in modified Boyden chambers (tissue culture-treated, 6.5-mm diameter, 8-*μ*m pore, Transwell; Dutscher, Brumath, France) as described previously ([@bib21]). Briefly, DMEM supplemented with 10% fetal bovine serum and 2% BSA was used as a chemoattractant. In total, 5 × 10^4^ cells were suspended in serum-free DMEM containing 0.2% BSA and seeded onto membranes coated with Matrigel (50 *μ*g cm^−2^). After a 6 h incubation period, cells were fixed with methanol and stained with crystal violet for 15 min. Cells remaining on the upper face of the membranes were scraped, and those on the lower face were counted using an inverted microscope. Experiments were reproduced three times in triplicates. Differences in cell invasiveness were evaluated by Student\'s *t*-test.

Statistical analysis
--------------------

Each experiment was performed at least three times from separate sets of culture and data were expressed as mean±s.e.m. Comparisons were performed using Student\'s *t*-test.

Results
=======

Influence of EDPs on Hsp90, pro-MMP-2 and uPA secretion by HT-1080
------------------------------------------------------------------

We previously demonstrated that EDPs upregulate invasiveness of tumour cells via the release of proteolytic enzymes. The mechanism leading to MMP-2- and uPA-increased release is unclear. We have not yet determined if this upregulation results from posttranscriptional mechanisms or increased enzyme stability. Heat-shock protein 90 is required for the activation and stabilisation of a wide variety of client proteins including MMP-2 and uPA, involved in promoting tumour invasiveness. Thus, we decided to study Hsp90 expression by HT-1080 after EDP stimulation. Serum-free culture media supplementation with EDPs (Kel 50 *μ*g ml^−1^) for 6--48 h did not induce HT-1080 cell growth. Those peptides have no cell toxicity as assessed by trypan blue exclusion (data not shown) and did not modify the overall protein content visualised by actin level in total cell extract from 6 to 48 h of culture ([Figure 1A](#fig1){ref-type="fig"}). Elastin-derived peptides stimulated pro-MMP-2 secretion by 4.5-, 2.5- and 2.1-fold at 6 h, 24 h and 48 h, respectively, as shown by zymography analysis ([Figure 1B](#fig1){ref-type="fig"}). Gelatin plasminogen zymography analysis revealed an increase in uPA secretion after EDP treatment by 2.3-, 2.0- and 1.4-fold at 6 h, 24 h and 48 h, respectively ([Figure 1C](#fig1){ref-type="fig"}). Heat-shock protein 90 secretion was also increased as soon as 6 h following supplementation of the culture medium with 50 *μ*g ml^−1^ of Kel. The maximum level of Hsp90 production (4.5-fold increase) by HT-1080 cells was found in the presence of 50 *μ*g ml^−1^ of Kel after 48 h of incubation ([Figure 1D](#fig1){ref-type="fig"}). As shown in [Figure 1E](#fig1){ref-type="fig"}, zymography and western blotting analysis of EDP-treated HT-1080 cell media indicated that Kel-mediated effect on the pro-MMP-2, uPA and Hsp90 secretion was concentration-dependent; a significant 2.4-fold increase in Hsp90 secretion was observed following supplementation of the culture medium with 25 *μ*g ml^−1^ of Kel and a 3.2-fold maximum increase of Hsp90 secretion by HT-1080 cells was found in the presence of 50 *μ*g ml^−1^ Kel. The increase of Hsp90, MMP-2 and uPA was also observed in the conditioned media of MDA-MB-231 breast carcinoma cells treated with EDP (50 *μ*g ml^−1^) for 24 h ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}).

Next, we examined whether other elastin peptides (VGVAPG, AGVPGLGVG and GRKRK) could also modulate Hsp90 production by HT-1080 cells, parallel to pro-MMP-2 and uPA secretion. While AGVPGLGVG and GRKRK peptides had no impact, HT-1080 cells grown in the presence of 200 *μ*g ml^−1^ VGVAPG for 24 h secreted significantly more pro-MMP-2 (1.8-fold), uPA (1.5-fold) and Hsp90 (1.9-fold) ([Figure 1E](#fig1){ref-type="fig"}) compared with control. Thus, EDPs stimulate proteases and Hsp90 secretion in a time- and concentration-dependent manner, and VGVAPG reproduced, at least partly, the EDP stimulation.

EDPs induce Hsp90, pro-MMP-2 and uPA synthesis by a posttranscriptional mechanism
---------------------------------------------------------------------------------

Total RNAs obtained from HT-1080 cells cultured at different time points (0, 5, 15, 30, 60, 120 min and 24 h) in the absence or presence of Kel (50 *μ*g ml^−1^) were analysed by real-time PCR. Kappa-elastin treatment induced only minor alteration of Hsp90 transcripts 1 and 2, MMP-2 and uPA mRNA levels from 5 to 120 min ([Supplementary Figure 2A--C](#sup1){ref-type="supplementary-material"}) and no statistical variation at 24 h either ([Supplementary Figure 2D](#sup1){ref-type="supplementary-material"}). These results suggest that Hsp90 increased secretion, and proteases release after EDP treatment may not implicate regulation at the transcriptional level. On the contrary, as previously reported for the MMP-2 and uPA expression ([@bib43]), the presence of EDPs rapidly enhanced Hsp90 protein synthesis; Kel (50 *μ*g ml^−1^) triggered a 4-fold induction of intracellular Hsp90 production after a 15 min incubation period and a maximal 4.5-fold induction after 30 min ([Figure 2A](#fig2){ref-type="fig"}) compared with control. Twenty-four-h Kel treatment maintained a 1.6-fold upregulated intracellular Hsp90 level ([Figure 2B](#fig2){ref-type="fig"}). Immunocytofluorescence study of Hsp90, pro-MMP-2 and uPA production by Kel-treated HT-1080 cells confirmed the upregulation of Hsp90, pro-MMP-2 and uPA synthesis ([Figure 2C--F](#fig2){ref-type="fig"}). A perinuclear colocalisation was highlighted for Hsp90 and pro-MMP-2, as well as for Hsp90 and uPA. These results demonstrate that EDPs induce Hsp90, pro-MMP-2 and uPa synthesis by a posttranscriptional mechanism.

Influence of EDP-dependent Hsp90 expression on the migratory and invasive properties of HT-1080 cells
-----------------------------------------------------------------------------------------------------

Under our experimental conditions ([@bib21]), untreated HT-1080 cells had a low ability to migrate and penetrate a Matrigel matrix, contrasting with the high capacity of those cells to migrate and invade in the presence of 50 *μ*g ml^−1^ Kel ([Figure 3A--C](#fig3){ref-type="fig"}). When untreated HT-1080 cells were incubated with either Hsp90 inhibitor geldanamycin (1.5 *μ*[M]{.smallcaps}) or radicicol (10 *μ*[M]{.smallcaps}), no change was detected in the migratory and invasive cell capacities *vs* control cells. Adding Kel (50 *μ*g ml^−1^) after geldanamycin or radicicol preincubation significantly reduced the wound closure by 6.5- and 4.6-fold, respectively ([Figure 3B and C](#fig3){ref-type="fig"}), and inhibited the cell invasion of Matrigel by 3.7- and 3.6-fold, respectively, as compared with cells treated with Kel alone ([Figure 3A](#fig3){ref-type="fig"}). Taken together, these results demonstrate that Hsp90 regulates EDP-stimulating effect on HT-1080 cells migratory and invasive capacities of HT-1080 cells.

Influence of Hsp90 on pro-MMP-2 and uPA expression by HT-1080 cells
-------------------------------------------------------------------

To determine if Hsp90 influences pro-MMP-2 and uPA expression, we performed zymography analysis on cell media pretreated with geldanamycin (1.5 *μ*[M]{.smallcaps}) or radicicol (10 *μ*[M]{.smallcaps}) and in the presence or absence of EDPs (50 *μ*g ml^−1^) ([Figure 4A](#fig4){ref-type="fig"}). For the cells incubated either with geldanamycin or radicicol alone, pro-MMP-2 expression was unaffected, while uPA expression was reduced. In cells treated with Kel, geldanamycin and radicicol significantly inhibited pro-MMP-2 (1.7- and 1.3-fold, respectively) and uPA synthesis (3.4- and 1.5-fold, respectively). We further investigated whether supplementation of culture media with Hsp90-blocking antibodies (0.1--10 *μ*g ml^−1^) could disrupt the EDP-dependent pro-MMP-2 and uPA expression. We observed that pro-MMP-2 and uPA levels in cell medium decreased with Hsp90 antibody in a concentration-dependent manner ([Figure 4B](#fig4){ref-type="fig"}). Although the Hsp90 antibody moderately blocked the uPA production (−35%), 10 *μ*g ml^−1^ of Hsp90 antibody induced a marked decrease of pro-MMP-2 secretion (3.3-fold decrease).

To explore the role of Hsp90α on pro-MMP-2 and uPA, we evaluated the impact of recombinant Hsp90α (rHsp90α) (1--50 *μ*g ml^−1^) on HT-1080 cells. As compared with EDP-treated cells, rHsp90α effect was concentration-dependent; significant and maximum increase of pro-MMP-2 and uPA was observed following supplementation of culture media with 50 *μ*g ml^−1^ of rHsp90α (2.0- and 2.9-fold respectively) ([Figure 4C](#fig4){ref-type="fig"}). Collectively, these results strongly support the idea that EDPs increase expression and secretion of Hsp90α, which, as an extracellular chaperone protein, may protect pro-MMP-2 and uPA from degradation and increase their content in the conditioned media.

Extracellular Hsp90 interacts with MMP-2 and uPA
------------------------------------------------

Our data show that EDPs enhance the expression of Hsp90, pro-MMP-2 and uPA. These three proteins are intracellularly colocalised. By affecting Hsp90 amount in the conditioned media, pro-MMP-2 and uPA were also affected. We thus studied if Hsp90 was able to interact with MMP-2 and uPA in the conditioned medium. After 24 h incubation with Kel (50 *μ*g ml^−1^), secreted Hsp90 was immunoprecipitated and Hsp90 client proteins were revealed by western blotting. As shown in [Figure 5](#fig5){ref-type="fig"}, we found that extracellular Hsp90 interacts with uPA and pro-MMP-2, and also with the MMP-2 active form. No enzymes were detected in the output, suggesting a complete interaction between those three extracellular proteins.

Hsp90 is essential for EDP-dependent pro-MMP-2 and uPA secretion
----------------------------------------------------------------

To confirm the essential role of Hsp90 in EDP-dependent pro-MMP-2 and uPA release, we transfected HT-1080 cells with two pools of Hsp90 siRNA (siRNA1 and siRNA2) or negative control siRNA (−) as described in Materials and Methods section. A strong decrease of Hsp90 mRNA expression (−88% and −86% for siRNA1 and siRNA2, respectively, compared with control) was observed 48 h after siRNA cell transfection ([Figure 6A](#fig6){ref-type="fig"}). To validate the Hsp90 knockdown, its protein expression pattern was analysed 72 h after transfection by western blotting. In siRNA1 and siRNA2 cells, 80% and 77% inhibition of Hsp90 protein expression was observed *vs* negative control siRNA ([Figure 6B](#fig6){ref-type="fig"}). In contrast, the actin expression was not affected by the Hsp90 siRNA. Heat-shock protein 90 knockdown was confirmed by immunocytofluorescence ([Figure 6C](#fig6){ref-type="fig"}). Forty-eight hours after transfection, siRNA-transfected cells were tested for pro-MMP-2 and uPA secretion in the absence or presence of EDPs for 24 h. The Hsp90 knockout by siRNA1 and siRNA2 affected the protease secretion compared with negative control siRNA-transfected cells (pro-MMP-2: −56 and −52% uPA: −61 and −64%, respectively) ([Figure 6D](#fig6){ref-type="fig"}). In the presence of 50 *μ*g ml^−1^ Kel, pro-MMP-2 and uPA amount still increased in the negative control siRNA cells (pro-MMP-2: 222% uPA: 225%). In the siRNA1- and siRNA2-transfected cells, Kel treatments only slightly increased pro-MMP-2 and uPA secretion. These results confirm that pro-MMP-2 and uPA secretions are independent of Hsp90 expression and that the EDP stimulation of pro-MMP-2 and uPA involves Hsp90.

Hsp90 protect secreted pro-MMP-2 and uPA from degradation
---------------------------------------------------------

To check pro-MMP-2 and uPA stability in the conditioned media, HT-1080 cells were treated with or without Kel (50 *μ*g ml^−1^) for 24 h. Collected conditioned media were incubated for 6, 24 and 48 h at +37 °C and analysed by gelatin zymography for pro-MMP-2 level and gelatin plasminogen zymography for uPA level. Pro-MMP-2 and uPA contents were decreased by 85% and 90%, respectively, in the control condition after 48 h of incubation at +37 °C and only by 26% and 30%, respectively, in the medium collected after Kel treatment. Addition of recombinant Hsp90 in the control conditioned medium (50 *μ*g ml^−1^) prevented pro-MMP-2 and uPA decrease, as observed in the Kel-treated conditioned medium ([Supplementary Figure 3](#sup1){ref-type="supplementary-material"}).

Discussion
==========

In this study, we showed that (a) EDPs increased the secretion of Hsp90; (b) this expression involved a rapid but stable posttranscriptional mechanism; (c) this EDP-dependent Hsp90 release was essential for cancer cell motility and their invasive capacities by increasing extracellular proteases. We first provided evidence that treatment of HT-1080 cells with EDPs increased Hsp90 production; a 4.5-fold increase in Hsp90 secretion was reached at 50 *μ*g ml^−1^ EDPs, a concentration close to those determined in physiological fluids ([@bib14]). This effect could be reproduced by the VGVAPG hexapeptide, thus involving the elastin complex receptor (S-Gal/PPCA/Neu1) in triggering Hsp90 production. We previously showed that the type VIII beta-turn conformation adopted by EDPs with GXXPG sequence was essential for inducing different MMP expression in fibroblasts ([@bib4]) and HT-1080 cells ([@bib21]). The existence of lactose-insensitive VGVAPG receptor on M27 carcinoma cells does not exclude the involvement of this type of EDP receptor in the Hsp90 secretion ([@bib3]).

In accordance with the stimulation of cell invasion, we showed that EDPs trigger at the same time the release of Hsp90, MMP-2 and uPA. Immunoprecipitation experiments suggested that these three extracellular proteins and the active form of pro-MMP-2 and MMP-2 were associated. This metzincin protease has largely been shown to be overexpressed in numerous cancers ([@bib6]) and its expression by tumour cells themselves or by stromal cells leads to high invasive abilities ([@bib30]). Urokinase plasminogen activator is also involved in tumour invasion by regulating plasminogen activation, leading to ECM degradation and to MMP activation ([@bib37]). Increased release of these two proteases by tumour cells could be implicated in the increased invasive capacities of invasive tumour cells treated with EDPs. The EDP-dependent Hsp90 secretion by cancer cells, combined with the protease release, could explain the exacerbation of the cancer cells\' invasive power in the presence of EDPs. The crucial role of extracellular Hsp90 on tumour metastasis and tumour angiogenesis has been demonstrated by the fact that rHsp90 promotes angiogenesis in an MMP-2-dependent manner, whereas Hsp90-blocking antibody suppresses it ([@bib13]; [@bib39]; [@bib41]). These previous studies have shown that extracellular Hsp90 interacts with pro-MMP-2, participating in the activation process and preventing the inactivation of MMP-2. They also showed that only Hsp90α isoform is present at the cell surface and in the conditioned media of HT-1080 fibrosarcoma cells.

Our studies are significant for several reasons. First, we confirm that extracellular Hsp90 regulates the presence of MMP-2 and demonstrate for the first time that it also regulates the presence of uPA in the pericellular environment. Both proteases interact with the extracellular Hsp90α and the inhibition of Hsp90 by specific inhibitors, and antibody- or siRNA-mediated gene silencing inhibits the MMP-2 and uPA accumulation in the conditioned media. Second, for the first time, we show that the expression and the secretion of Hsp90α are controlled by the interaction of EDPs with cell surface receptor. The existence of extracellular Hsp90α has long been observed and its secretion is considered to use an unconventional way because of the lack of N-terminal signal peptide ([@bib45]; [@bib8]). However, the regulatory mechanism of Hsp90α secretion is still poorly understood. Some studies relate the fact that Hsp90α secretion was enhanced under stress conditions, such as hypoxia and oxidative stress ([@bib26]; [@bib9]; [@bib25]). The question then arises of how those different stimuli lead to Hsp90α secretion.

Among the proteases secreted by cancer cells following EDP treatment, MMP-2 is also an efficient elastase ([@bib35]). In addition to the fact that binding of pro-MMP-2 to elastin modulates its proteolytic activation ([@bib12]), the further fragmentation of elastin matrix owing to the EDP-induced MMP-2 secretion can lead to an increased production of EDPs, resulting in a vicious circle where more EDPs promote more invasion and in turn generating more EDPs. Breaking this exacerbation mechanism by blocking EDP effects with elastin receptor antagonists could be beneficial in these circumstances.

The increased Hsp90 and protease release/accumulation was not related to a transcriptional effect as mRNA encoding Hsp90α, MMP-2 and uPA were not modified. Tumour microvesicles have been linked to Hsp90 secretion ([@bib19]), and tumour invasion via release of MMP-2 and uPA ([@bib15]; [@bib1]; [@bib11]; [@bib10]). Thus, the lack of transcriptional effect, in combination with the very quick appearance of the effects of EDPs on Hsp90 protein synthesis (15 min of treatment) evokes a post-transcriptional mechanism stimulated by EDPs. A release of Hsp90 and proteases by microvesicles followed by an extracellular Hsp90 stabilisation and activation of proteases may be suggested.

In summary, our study pinpoints, for the first time, EDPs\' protumoural key role by inducing Hsp90 secretion, which results in stabilisation and activation of proteases, and finally in tumour dissemination. The EDP-dependent Hsp90 secretion reinforces the fact that initial elastolysis by serine elastases from inflammatory cells or several members of the MMP family in elastin-rich tissues such as the lung, skin and breast must be considered as a main catalytic event in tumour progression.
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![**EDPs influence on Hsp90, pro-MMP-2 and uPA secretion.** (**A**) Gelatin zymography, gelatin plasminogen zymography and western blotting analysis of conditioned media and actin content in total cell extracts from HT-1080 cells cultured for 6, 24 and 48 h in the absence (−) or presence of 50 *μ*g ml^−1^ Kel (+) as described in Materials and Methods section. (**B**) Quantitative evaluation of pro-MMP-2 secretion by HT-1080 cells on gelatin zymography. Results (mean±s.e.m.) were expressed as the percentage of control 6 h (EDP-untreated cells). \**P*\<0.005, \*\**P*\<0.001, significantly different from control. Lighter bars, untreated cells; black bars, EDP-treated cells. (**C**) Quantitative evaluation of uPA secretion by HT-1080 cells on gelatin plasminogen zymography. Results (mean±s.e.m.) were expressed as the percentage of control for 6 h (EDP-untreated cells). \**P*\<0.005, \*\**P*\<0.001, significantly different from control. Lighter bars, untreated cells; black bars, EDP-treated cells. (**D**) Quantitative evaluation of Hsp90 secretion by HT-1080 cells by western blotting. Results (mean±s.e.m.) were expressed as the percentage of control for 6 h (EDP-untreated cells). \*\**P*\<0.001, significantly different from control. Lighter bars, untreated cells; black bars, EDP-treated cells. (**E**) Dose-effect study of EDP treatment (Kel 0--100 *μ*g ml^−1^) on pro-MMP-2, uPA and Hsp90 secretion. Gelatin zymography, gelatin plasminogen zymography and western blotting analysis of conditioned media and actin content in cell extracts from HT-1080 cells cultured for 24 h in the absence (Ctl) or in the presence of 1--100 *μ*g ml^−1^ Kel. (**F**) Gelatin zymography, gelatin plasminogen zymography and western blotting analysis of conditioned media from HT-1080 cells cultured for 24 h in the absence (Ctl) or in the presence of 50 *μ*g ml^−1^ Kel (Kel) or synthetic elastin peptides (VGVAPG, AGVPGLGVG, GRKRK). All synthetic peptides were used at 200 *μ*g ml^−1^. Quantitative evaluation of protein secretions by HT-1080 cells on gelatin zymography, gelatin plasminogen zymography and by western blotting. Results (mean±s.e.m.) were expressed as the percentage of control (EDP-untreated cells).](bjc2014239f1){#fig1}

![**Evaluation of the intracellular Hsp90, MMP-2 and uPA expression in HT-1080 cells.** (**A**) Western blotting analysis of intracellular Hsp90 using a rabbit anti-Hsp90 monoclonal antibody and probing with anti-actin antibody were carried out as described in Materials and Methods section. (**B**) Western blotting analysis of intracellular Hsp90 at 24 h using a rabbit anti-Hsp90 monoclonal antibody and probing with anti-actin. (**C**--**F**) Localisation of Hsp90, pro-MMP-2 and uPA in HT-1080 cells in the presence (**D**, **F**) (Kel 50 *μ*g ml^−1^) or absence (**C**, **E**) (control) of EDPs. Cells were cultured on glass slides, fixed with paraformaldehyde and labelled with an anti-Hsp90 (green), anti-pro-MMP-2 form (red) (**C**, **D**), anti-uPA (red) (**E**, **F**). Yellow staining corresponds to areas where Hsp90, pro-MMP-2 or uPA colocalised. Scale bar: 10 *μ*m.](bjc2014239f2){#fig2}

![**Hsp90 regulates migration and invasion of EDP-treated HT-1080 cells.** (**A**) Geldanamycin and radicicol, two Hsp90 inhibitors, block the Matrigel invasion of EDP-stimulated HT-1080 cells. HT-1080 cells were incubated with 1.5 *μ*[M]{.smallcaps} geldanamycin or 10 *μ*[M]{.smallcaps} radicicol during 1 h before being stimulated or not for 6 h with 50 *μ*g ml^−1^ EDPs. At the end of the incubation period, cells were fixed with methanol and stained with crystal violet for 15 min. Cells remaining on the upper face of the membranes were scrapped and those on the lower face were counted. Data are expressed as mean±S.E.M. values from three independent experiments, each performed in triplicate. \*\**P*\<0.001, significantly different from Kel alone). Lighter bars, untreated cells; black bars, EDP-treated cells. (**B**) Heat-shock protein 90 inhibitors (geldanamycin and radicicol) inhibit the EDP-stimulated migration of HT-1080 cells. HT-1080 cells have been seeded in 12-well plates and a homogeneous wound was created in each well by scraping cells with a tip. Cells were incubated with 1.5 *μ*[M]{.smallcaps} geldanamycin or 10 *μ*[M]{.smallcaps} radicicol during 1 h before being stimulated or not for 24 h with 50 *μ*g ml^−1^ EDPs and cell migration was evaluated by microscopy. (**C**) Quantification of the wound closure. \*\**P*\<0.001, significantly different from Kel alone.](bjc2014239f3){#fig3}

![**EDP increases extracellular Hsp90 and promotes pro-MMP-2 and uPA accumulation in HT-1080 culture media.** (**A**) Gelatin zymography and gelatin plasminogen zymography analysis of Hsp90 inhibitors effect (1.5 *μ*[M]{.smallcaps} geldanamycin and 10 *μ*[M]{.smallcaps} radicicol) on the production of pro-MMP-2 and uPA in the presence (+: 50 *μ*g ml^−1^) or in the absence (−) of EDPs (24 h of treatment). (**B**) Quantitative evaluation of protein secretions by HT-1080 cells on gelatin zymography and gelatin plasminogen zymography. Results (mean±s.e.m.) were expressed as the percentage of control (EDP-untreated cells). \**P*\<0.005, \*\**P*\<0.001, significantly different from Kel alone. (**C**) Gelatin zymography and gelatin plasminogen zymography analysis of monoclonal anti-Hsp90 antibody effect on the production of pro-MMP-2 and uPA in EDP-treated HT-1080 cells (50 *μ*g ml^−1^) (24 h of treatment). (**D**) Quantitative evaluation of protein secretions by HT-1080 cells on gelatin zymography and gelatin plasminogen zymography. Results (mean±s.e.m.) were expressed as the percentage of control (EDP-untreated cells). \**P*\<0.005, \*\**P*\<0.001, significantly different from Kel alone. (**E**) Gelatin zymography and gelatin plasminogen zymography analysis of the effect of recombinant Hsp90*α* protein on the production of pro-MMP-2 and uPA by HT-1080 cells (24 h of treatment). (**F**) Quantitative evaluation of protein secretions by HT-1080 cells on gelatin zymography and gelatin plasminogen zymography. Results (mean±s.e.m.) were expressed as the percentage of control (EDP-untreated cells). \**P*\<0.005, \*\**P*\<0.001, significantly different from control.](bjc2014239f4){#fig4}

![**Hsp90 interacts with MMP-2 and uPA.** Immunoprecipitation of extracellular Hsp90 from EDP-treated HT-1080 cells\' conditioned media and bound MMP-2 and uPA analysis by western blotting. Output 100% represent the unbound protein after Hsp90 immunoprecipitation.](bjc2014239f5){#fig5}

![**Effect of Hsp90 knockdown on the EDP-regulated pro-MMP-2 and uPA secretion by HT-1080 cells.** (**A**) Real-time PCR analysis of Hsp90α transcript 2 mRNA relative expression 48 h after treatment with Hsp90 siRNA *vs* negative control siRNA-treated cells (−). Results (mean±s.e.m.; *n*=3) were expressed as the ratio of Hsp90α transcript 1 mRNA to EEF1a1 mRNA. (**B**) Western blotting analysis and quantification of intracellular Hsp90 using a rabbit anti-Hsp90 monoclonal antibody and probing with anti-actin 72 h after treatment with Hsp90 siRNA *vs* negative control siRNA-treated cells (−) as described in Materials and Methods section. Results (mean±s.e.m.) were expressed as the percentage of negative control siRNA-treated cells (EDP-untreated cells). (**C**) Immunolocalisation of Hsp90 72 h after treatment with siRNA to Hsp90 mRNA *vs* negative control siRNA-treated cells (−). Cells were cultured on glass slides, fixed with paraformaldehyde and labelled with an anti-Hsp90 antibody (green). Scale bar: 20 *μ*m. (**D**) Gelatin zymography, gelatin plasminogen zymography and western blotting analysis of conditioned media in the presence (+: 50 *μ*g ml^−1^) or in the absence (−) of EDPs 72 h after treatment with Hsp90 siRNA *vs* negative control siRNA-treated cells. Quantitative evaluation of protein secretions by HT-1080 cells on gelatin zymography, gelatin plasminogen zymography and by western blotting. Results (mean±s.e.m.) were expressed as the percentage of control (negative control siRNA/EDP-untreated cells).](bjc2014239f6){#fig6}
